4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $29.88 Consensus Price Target from Brokerages

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have earned an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $29.8750.

A number of brokerages recently commented on FDMT. The Goldman Sachs Group set a $33.00 price target on 4D Molecular Therapeutics in a report on Friday, May 8th. Jefferies Financial Group restated a “buy” rating and set a $21.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a research note on Monday, March 30th. Royal Bank Of Canada lifted their price objective on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the stock an “outperform” rating in a report on Thursday, March 19th. Wall Street Zen downgraded shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Monday, April 20th.

Insiders Place Their Bets

In other news, insider Scott Bizily sold 9,810 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total transaction of $117,720.00. Following the transaction, the insider directly owned 8,617 shares of the company’s stock, valued at approximately $103,404. This trade represents a 53.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David Kirn sold 114,746 shares of the business’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $10.47, for a total transaction of $1,201,390.62. Following the sale, the insider owned 942,485 shares in the company, valued at $9,867,817.95. This trade represents a 10.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 126,478 shares of company stock worth $1,338,369 over the last three months. Corporate insiders own 7.90% of the company’s stock.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Hedge funds have recently made changes to their positions in the business. RA Capital Management L.P. grew its position in 4D Molecular Therapeutics by 23.9% during the 4th quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock worth $42,399,000 after purchasing an additional 1,090,000 shares in the last quarter. Janus Henderson Group PLC raised its position in 4D Molecular Therapeutics by 13.2% during the first quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock valued at $48,868,000 after buying an additional 611,276 shares during the period. Goldman Sachs Group Inc. raised its position in 4D Molecular Therapeutics by 4.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 4,302,905 shares of the company’s stock valued at $32,272,000 after buying an additional 174,489 shares during the period. State Street Corp lifted its stake in 4D Molecular Therapeutics by 197.5% in the 4th quarter. State Street Corp now owns 2,688,880 shares of the company’s stock worth $20,167,000 after acquiring an additional 1,785,106 shares in the last quarter. Finally, Armistice Capital LLC boosted its position in 4D Molecular Therapeutics by 76.6% during the 4th quarter. Armistice Capital LLC now owns 1,936,000 shares of the company’s stock worth $14,520,000 after acquiring an additional 840,000 shares during the period. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Trading Up 0.8%

Shares of FDMT stock opened at $12.82 on Friday. The company’s fifty day simple moving average is $10.00 and its 200-day simple moving average is $9.25. The company has a market cap of $670.23 million, a PE ratio of -4.99 and a beta of 2.70. 4D Molecular Therapeutics has a 52 week low of $3.98 and a 52 week high of $14.00.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The company had revenue of $3.05 million during the quarter, compared to analyst estimates of $2.59 million. 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. Equities research analysts expect that 4D Molecular Therapeutics will post -4.14 EPS for the current fiscal year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.